AstraZeneca said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet ...
AstraZeneca (NASDAQ:AZN) announced Tuesday that its FDA-approved breast cancer therapy, Truqap (capivasertib), did not reach ...
, opens new tab said on Monday its drug for a rare, aggressive form of breast cancer did not meet the main goal of overall survival in a late-stage trial. G1's drug trilaciclib was tested in 187 ...
While AstraZeneca’s Truqap bears the distinction of being the first AKT inhibitor to pass muster with the U.S. | In the ...
The CAPItello-290 Phase III trial evaluated Truqap in patients with advanced or metastatic triple-negative breast cancer.
AstraZeneca Plc’s lung and breast cancer drugs significantly slowed the spread of disease in two trials, potentially establishing the medicines as the new standard of care for some patients. The ...
British drug major AstraZeneca Plc. (AZN.L, AZN) announced Tuesday that the CAPItello-290 Phase III trial for Truqap (capivasertib) ...
Susan Galbraith, Ph.D. (AstraZeneca) AZ and Daiichi have not yet unveiled their front-line strategy for Enhertu in HER2-low breast cancer. But AZ’s Galbraith hinted at the possibility of a more ...
AstraZeneca and Daiichi Sankyo’s Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy – even if they had very low levels ...
Himachal Pradesh fail quality test conducted by CDSCO. Samples declared sub-standard, with majority from Baddi. Drugs used ...
Breast cancer drug Truqap, manufacturer AstraZeneca, failed main goal in CAPItello-290 trial for metastatic triple-negative ...
AstraZeneca and Daiichi Sankyo’s Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy – even if they had very low levels ...